Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Tivic Health files patent for personalized VNS device | 2 | Investing.com | ||
Mo | Tivic Health meldet Patent für personalisiertes VNS-Gerät an | 2 | Investing.com Deutsch | ||
24.02. | Former Statera CEO Michael Handley named Tivic Biopharma president | 1 | Seeking Alpha | ||
TIVIC HEALTH SYSTEMS Aktie jetzt für 0€ handeln | |||||
24.02. | Tivic Health Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
05.02. | Tivic Health Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
03.01. | Tivic Health Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
23.12.24 | Tivic Health Systems, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.11.24 | Tivic Health Systems GAAP EPS of -$0.23, revenue of $126K | 8 | Seeking Alpha | ||
15.11.24 | Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update | 170 | Business Wire | FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months... ► Artikel lesen | |
14.11.24 | Tivic completes enrollment in nerve stim trial | 1 | MassDevice | ||
12.11.24 | Tivic Health Systems, Inc.: Tivic Health Validates European Patents in Great Britain, Germany, and France | 288 | Business Wire | Patents cover methods used to identify key treatment points and dynamically personalize simulation
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing... ► Artikel lesen | |
18.09.24 | Tivic Health macht Fortschritte bei nicht-invasiver Nervenstimulation | 13 | Investing.com Deutsch | ||
18.09.24 | Tivic Health advances in non-invasive nerve stimulation | 1 | Investing.com | ||
17.09.24 | Tivic Health partners with Fletcher Spaght for growth strategy | 2 | Investing.com | ||
13.09.24 | Tivic Health names Lisa Wolf as interim CFO | 1 | Seeking Alpha | ||
13.09.24 | Tivic Health Systems, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
14.08.24 | Tivic Reports Second Quarter 2024 Financial Results | 206 | Business Wire | SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter... ► Artikel lesen | |
23.07.24 | Tivic Health Systems, Inc.: Tivic Health Expands Intellectual Property Portfolio | 369 | Business Wire | Three New Patents Granted in the US and Europe Tivic Health® Systems, Inc. ("Tivic Health", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced... ► Artikel lesen | |
15.05.24 | Tivic Reports First Quarter 2024 Financial Results and Subsequent Events | 161 | Business Wire | SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its first quarter... ► Artikel lesen | |
25.03.24 | Tivic Reports Fiscal Year 2023 Financial Results | 573 | Business Wire | SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. ("Tivic", Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,130 | -2,26 % | Sernova Biotherapeutics Inc: Sernova receives FDA clearance for IND application | ||
ATOSSA THERAPEUTICS | 0,726 | +2,98 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
PING AN HEALTHCARE | 0,963 | +1,56 % | Ping An Healthcare and Technology Company Limited: Ping An Health Pioneers AI-Driven Healthcare with DeepSeek Integration | HONG KONG and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,022 | +18,48 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,510 | +10,87 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
CYTOSORBENTS | 1,060 | +7,29 % | CytoSorbents sichert sich 1,6 Millionen US-Dollar durch Optionsscheinausübungen | ||
VERU | 0,472 | -1,99 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 0,770 | +2,67 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
VOLITIONRX | 0,591 | -4,88 % | VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 14, 2024... ► Artikel lesen | |
EKSO BIONICS | 0,498 | +7,56 % | EKSO BIONICS HOLDINGS, INC. Q4 Sales Increase | ||
IMUNON | 0,765 | -7,27 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
BEYOND AIR | 0,256 | +3,23 % | Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update | Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international... ► Artikel lesen | |
AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
NOVACYT | 0,571 | 0,00 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
AROVELLA THERAPEUTICS | 0,062 | +4,20 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |